Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Glycerol Phenylbutyrate (Ravicti) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
Reference | Reason for Exclusion |
---|---|
Glycerol phenylbutyrate (Ravicti) for urea cycle disorders. Med Lett Drugs Ther. 2014 Aug 18;56(1449):77–8. | Not randomized controlled trial (RCT) |
- EXCLUDED STUDIES - Glycerol Phenylbutyrate (Ravicti)EXCLUDED STUDIES - Glycerol Phenylbutyrate (Ravicti)
- LITERATURE SEARCH STRATEGY - Glycerol Phenylbutyrate (Ravicti)LITERATURE SEARCH STRATEGY - Glycerol Phenylbutyrate (Ravicti)
- SUMMARY OF EFFICACY AND SAFETY RESULTS IN THREE SHORT-TERM, NON-RANDOMIZED STUDI...SUMMARY OF EFFICACY AND SAFETY RESULTS IN THREE SHORT-TERM, NON-RANDOMIZED STUDIES: UP 1204-003, HPN-100-005, AND HPN-100-012 - Glycerol Phenylbutyrate (Ravicti)
- DETAILED OUTCOME DATA - Ustekinumab (Stelara)DETAILED OUTCOME DATA - Ustekinumab (Stelara)
- CONCLUSIONS - Glycerol Phenylbutyrate (Ravicti)CONCLUSIONS - Glycerol Phenylbutyrate (Ravicti)
Your browsing activity is empty.
Activity recording is turned off.
See more...